CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
拆解复发/难治性套细胞淋巴瘤
英文原题：Dismantling relapsed/refractory mantle cell lymphoma.
查看英文原题
Dismantling relapsed/refractory mantle cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管非霍奇金淋巴瘤领域的治疗近期取得了进展，但复发/难治性（R/R）套细胞淋巴瘤（MCL）的有效治疗仍是一项挑战。Bruton酪氨酸激酶（BTK）抑制剂的开发彻底改变了这一领域，这些药物现已成为R/R MCL管理的主要手段。然而，BTK抑制剂并非治愈性，且随着它们越来越多地被纳入一线方案，R/R疾病不断变化的治疗格局带来了新的挑战。本文综述了常用治疗策略的数据，包括BTK抑制剂、BCL2抑制剂venetoclax、基于来那度胺的方案以及CAR-T 细胞疗法。我们还综述了有前景的新药数据，包括抗体药物偶联物和双特异性抗体，随后重点介绍了一些新兴靶向药物，这些药物继续为改善R/R MCL的结局带来希望。
展开英文摘要原文
Despite recent therapeutic advancements in the general field of non-Hodgkin lymphoma, effective treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL) remains a challenge. The development of Bruton tyrosine kinase (BTK) inhibitors has revolutionized the field and these agents are now the mainstay of R/R MCL management.
However, BTK inhibitors are not curative, and as they are increasingly being incorporated into frontline regimens, the shifting treatment landscape for R/R disease presents new challenges.
Here we review data for commonly employed treatment strategies including BTK inhibitors, the BCL2-inhibitor venetoclax, lenalidomide-based regimens, and chimeric antigen receptor T-cell therapy.
We additionally review data for promising novel agents including antibody-drug conjugates and bispecific antibodies before highlighting some emerging targeted agents that continue to bring promise for improved outcomes in R/R MCL.
论文信息
- 作者
- Ryan CE、Kumar A
- 单位
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: christine_ryan@dfci.harvard.edu.United States
- 文献类型
- 综述 · 美国政府（非公共卫生署）资助研究
- 期刊
- Blood reviews2024 Sep
- 原文标识
- PubMed 38906740 · DOI 10.1016/j.blre.2024.101221